TechInvention offers single dose COVID-19 vaccine

TechInvention Lifecare, a biotech startup company based out of Mumbai, has claimed positive outcomes of its recombinant subunit SARS-CoV-2 vaccine (CoviTech) in a single dose preliminary study. The company is now advancing further development of the vaccine. In CoviTech, the antigen is expressed in yeast Pichia pastoris, one of the most desirable expression platforms in recombinant technology to produce cost-effective products with high yield and easy scale-up process. Products like the Hepatitis B vaccine manufactured using the same platform technology are being administered even to newborns with exceptional safety, according to the company sources. While CoviTech is being positioned as an affordable, effective and safe vaccine for the masses, the startup is also exploring another vaccine candidate targeting the conserved and immunogenic regions of the virus. This vaccine may have the potential to address the burning issue of mutations.